JP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41
Benzinga Newsdesk 4 weeks ago
Analyst RatingsNewsInitiationPrice Target
JP Morgan analyst Priyanka Grover initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Overweight rating and announces Price Target of $41.
JP Morgan analyst Priyanka Grover initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Overweight rating and announces Price Target of $41.